Back to top
more

H Lundbeck A/S (HLUYY)

(Delayed Data from OTC)

$43.01 USD

43.01
1,318

+0.33 (0.77%)

Updated May 3, 2019 03:45 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Merck (MRK) Presents New Data from Januvia Diabetes Studies

by Zacks Equity Research

Merck (MRK) produces new data from two studies on type II diabetes medicine Januvia (sitagliptin), which supports the drug's clinical profile.

    Zacks Industry Outlook Highlights: H. Lundbeck, Eli Lilly, GlaxoSmithKline and Novartis

    by Zacks Equity Research

    Zacks Industry Outlook Highlights: H. Lundbeck, Eli Lilly, GlaxoSmithKline and Novartis

      Large Cap Pharma Stock Outlook: Short-Term Struggle Likely

      by Zacks Equity Research

      Drug pricing scrutiny, pricing and competitive pressure, and major pipeline setbacks can hurt the performance of the large-cap pharmaceuticals sector in the short term.

        AstraZeneca's Tagrisso Wins EU Nod for First-Line Lung Cancer

        by Zacks Equity Research

        AstraZeneca's (AZN) Tagrisso gets an EU nod for first-line treatment of advanced or metastatic non-small cell lung cancer in patients with epidermal growth factor receptor (EGFR) mutations.

          J&J Receives Buyout Offer for Sterilization Products Unit

          by Zacks Equity Research

          Johnson & Johnson (JNJ) receives a binding offer worth $2.8 billion from Fortive Corporation for its sterilization products business.

            Pfizer's Tafamadis Gets Breakthrough Therapy Designation

            by Zacks Equity Research

            Pfizer's (PFE) rare disease candidate, tafamidis, gets Breakthrough Therapy designation in the United States for the treatment of transthyretin cardiomyopathy.

              Pfizer's Rare Disease Candidate Meets Endpoint in Phase III

              by Zacks Equity Research

              Pfizer's (PFE) pipeline candidate tafamidis, developed for the treatment of transthyretin cardiomyopathy (TTR-CM), meets the main goal in a late-stage study.

                Kinjel Shah headshot

                4 Top-Ranked Drug/Biotech Stocks to Buy as Q1 Nears End

                by Kinjel Shah

                The first quarter of 2018 is drawing to a close. With the outlook optimistic for the rest of the year, we highlight four drug/biotech stocks worth buying

                  Pfizer's Xtandi Label Expansion Filing Gets Priority Review

                  by Zacks Equity Research

                  FDA grants priority review status to Pfizer's(PFE) sNDA to expand the label of Xtandi to include the non-metastatic prostate cancer patient population.

                    4 Buy-Ranked Large Cap Pharma Stocks to Boost Your Portfolio

                    by Zacks Equity Research

                    Though the large-cap pharma sector struggled a little after a strong start in 2018, it is largely expected to rebound as the year progresses.

                      Pfizer Gets Mixed Feedback on Cancer Treatments From CHMP

                      by Zacks Equity Research

                      CHMP recommends in favor of two hematology medicines of Pfizer (PFE) while recommending against label expansion of kidney cancer drug, Sutent.

                        Bristol-Myers (BMY) Beats on Q4 Earnings, Eliquis Impresses

                        by Zacks Equity Research

                        Bristol-Myers (BMY) beats estimates on both counts in the fourth quarter. Eliquis records solid sales.

                          Charles Schwab, El Paso Energy, BP, Asahi Kasei and H Lundbeck A/S highlighted as Zacks Bull and Bear of the Day

                          by Zacks Equity Research

                          Charles Schwab, El Paso Energy, BP, Asahi Kasei and H Lundbeck A/S highlighted as Zacks Bull and Bear of the Day

                            John Blank headshot

                            Goldilocks Growth Bulls vs. Valuation Bears: Global Week Ahead

                            by John Blank

                            This is a 'Goldilocks' period for world markets. Everything is just right: the global economy is booming, company profits are rising, the central bank stimulus taps are still open and U.S. tax cuts are about to kick in.

                              Strength Seen in AbbVie (ABBV): Stock Soars 13.8%

                              by Zacks Equity Research

                              AbbVie (ABBV) saw a big move last session, as its shares jumped nearly 14% on the day, amid huge volumes.

                                Pfizer's Leukemia Drug Gets FDA Nod in First-Line Setting

                                by Zacks Equity Research

                                Pfizer's (PFE) leukemia drug Bosulif receives FDA approval in first-line setting.

                                  Biogen, Ionis Ink Deal for Spinal Muscular Atrophy Therapies

                                  by Zacks Equity Research

                                  Biogen (BIIB) expands collaboration with Ionis to identify new drug candidates for the treatment of SMA.

                                    Pfizer Hikes Dividend, Announces $10B Share Buyback Plan

                                    by Zacks Equity Research

                                    Pfizer (PFE) raises quarterly dividend for 2018 while also authorizing a new $10 billion share repurchase program.

                                      Sanofi Wins FDA Approval for Biosimilar of Lilly's Humalog

                                      by Zacks Equity Research

                                      Sanofi's (SNY) Admelog, a follow-on biologic version of Lilly's Humalog, received FDA approval.

                                        AbbVie Psoriasis Candidate Succeeds in 4th Phase III Study

                                        by Zacks Equity Research

                                        AbbVie (ABBV) announces data from a phase III study on risankizumab, which shows that a significant portion of plaque psoriasis patients treated with risankizumab achieved high levels of skin clearance.

                                          Pfizer/Merck KGaA's Bavencio Fails in Gastric Cancer Study

                                          by Zacks Equity Research

                                          Pfizer & Merck KGaA's (MKGAF) Bavencio/avelumab fails in a phase III study evaluating it for the treatment of gastric cancer in the third-line setting.

                                            Teva/Nuvelution to Speed Up Development of Austedo in US

                                            by Zacks Equity Research

                                            Teva Pharma (TEVA) and Nuvelution inked a deal to accelerate the development of Austedo (deutetrabenazine) tablets for the treatment of tics associated with Tourette syndrome.

                                              4 Biotech Stocks That Show Promise on Sustainable Growth

                                              by Zacks Equity Research

                                              Biotech sector is performing well in 2017 due to an increase in FDA approvals, new product sales ramp up, R&D success and innovation, strong clinical study results and continued strong performance of legacy products.

                                                Teva's Leukemia Drug sNDA Granted Priority Review by the FDA

                                                by Zacks Equity Research

                                                Teva Pharmaceutical's (TEVA) sNDA for label expansion of Trisenox as first-line treatment of acute promyelocytic leukemia has been accepted by the FDA under priority review.

                                                  Teva's New CEO Brings No Relief: Generic Drugmakers to Dump

                                                  by Zacks Equity Research

                                                  The New CEO appointment at Teva (TEVA has once again shifted focus to the Generic Drug industry, which is presently facing several challenges.